> top > docs > PubMed:25314077 > annotations

PubMed:25314077 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-86 Sentence denotes Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.
T2 87-251 Sentence denotes Constitutive NF-κB signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-κB-targeting strategies lack cancer cell specificity.
T3 252-397 Sentence denotes Here, we identify the interaction between the NF-κB-regulated antiapoptotic factor GADD45β and the JNK kinase MKK7 as a therapeutic target in MM.
T4 398-584 Sentence denotes Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45β/MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells.
T5 585-722 Sentence denotes DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in vitro.
T6 723-825 Sentence denotes Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses.
T7 826-957 Sentence denotes Hence, cancer-selective targeting of the NF-κB pathway is possible and, at least for myeloma patients, promises a profound benefit.
T1 0-86 Sentence denotes Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.
T2 87-251 Sentence denotes Constitutive NF-κB signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-κB-targeting strategies lack cancer cell specificity.
T3 252-397 Sentence denotes Here, we identify the interaction between the NF-κB-regulated antiapoptotic factor GADD45β and the JNK kinase MKK7 as a therapeutic target in MM.
T4 398-584 Sentence denotes Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45β/MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells.
T5 585-722 Sentence denotes DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in vitro.
T6 723-825 Sentence denotes Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses.
T7 826-957 Sentence denotes Hence, cancer-selective targeting of the NF-κB pathway is possible and, at least for myeloma patients, promises a profound benefit.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 137-153 HP_0006775 denotes multiple myeloma
T2 169-176 HP_0002664 denotes cancers
T3 227-233 HP_0002664 denotes cancer
T4 689-695 HP_0002664 denotes cancer
T5 833-839 HP_0002664 denotes cancer